ContraFect Corporation (Nasdaq:CFRX), a
clinical-stage biotechnology company focused on the discovery and
development of protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, today
announced the presentation of data on its lead drug candidate
CF-301 at the 28th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) to be held from April 21-24, 2018, in
Madrid, Spain.
The presentations include results from in vitro,
in vivo and microbiologic surveillance studies of ContraFect’s
lead lysin CF-301, which is currently being evaluated in a Phase 2
clinical trial as a potential treatment for Staphylococcus aureus
(Staph aureus) bacteremia, including endocarditis. Topics to be
covered include CF-301’s synergy with standard of care antibiotics
(SOC) including optimal timing of CF-301 administration relative to
SOC and suppression of resistance to SOC; anti-biofilm activity
against ‘human’ biofilm; and activity against contemporary clinical
isolates of Staph aureus collected at centers in Europe. The
presentations include one oral session and four poster
sessions.
“We are pleased to return to ECCMID to present
new data on the activity of CF-301, our first-in-class lysin
candidate. We are excited to present for the first time,
experimental results demonstrating CF-301’s ability to eradicate
biofilms formed in the clinical setting of a catheter-related
bloodstream infection” said Cara Cassino, M.D., Chief Medical
Officer and Executive Vice President of Research and Development at
ContraFect. “In addition, we will present important data from
studies using the rabbit infectious endocarditis model which
further confirms the potent ability of CF-301, dosed at or below
the Phase 2 dose, to potentiate bactericidal activity through
synergy with anti-staphylococcal antibiotics. These findings
further support the superiority design of our ongoing study to
evaluate CF-301 used in addition to SOC antibiotics. We continue to
look forward to announcing top-line results from this Phase 2 trial
in the fourth quarter of 2018,” continued Dr. Cassino.
Presentation Details:
Presentation
Title: Efficacy of lysin CF-301 in
addition to daptomycin or vancomycin in a rabbit model of infective
endocarditis due to methicillin-resistant Staph aureus (MRSA)
Oral Presentation Day & Time: Sunday,
April 22, 2018, 5:46 p.m. – 5:56 p.m. CEST (11:46 a.m. – 11:56 a.m.
EDT) Abstract Number: #O0581 Session
Title: Drug combinations: pre-clinical evidence
Presentation
Title: Translational study of the
antibiofilm activity of lysin CF-301 in an infected hemodialysis
catheter from patient with suspected Staph aureus bacteremia
Session Day & Time: Monday, April 23,
2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P1435 Session
Title: Biofilms I - Gram-positive pathogens
Presentation
Title: European surveillance study
of CF-301 activity against contemporary Staph aureus isolates from
Italy, Greece, and Hungary Session Day &
Time: Tuesday, April 24, 2018, 12:30 p.m. – 1:30 p.m.
CEST (6:30 a.m. – 7:30 a.m. EDT) Abstract
Number: #P2450 Session
Title: Phages and therapeutic antibodies
Presentation
Title: Optimal timing of the
Co-administration of lysin CF-301 with daptomycin in a rabbit model
of infective endocarditis due to MRSA Session Day &
Time: Tuesday, April 24, 2018, 12:30 p.m. – 1:30 p.m.
CEST (6:30 a.m. – 7:30 a.m. EDT) Abstract
Number: #P2451 Session
Title: Phages and therapeutic antibodies
Presentation
Title: Lysin CF-301 exhibits a low
propensity for decreased susceptibility and prevents daptomycin
resistance in a rabbit model of Staph aureus infective endocarditis
Session Day & Time: Tuesday, April 24,
2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P2452 Session
Title: Phages and therapeutic antibodies
The abstracts can be accessed through
the ECCMID website. Following the meeting, the presentation
posters will be available on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing therapeutic protein and antibody
products for life-threatening, drug-resistant infectious diseases,
particularly those treated in hospital settings. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses (regions that are
not prone to mutation). ContraFect's initial product candidates
include new agents to treat antibiotic-resistant infections such as
MRSA (Methicillin-resistant Staph aureus) and influenza.
ContraFect’s lead product candidate, CF-301, is currently in a
Phase 2 clinical trial for the treatment of Staphylococcus aureus
bacteremia, including endocarditis and is the first lysin to enter
clinical studies in the U.S. ContraFect is also conducting
research focused on the discovery of lysins to target Gram-negative
bacteria.
About CF-301:
CF-301 is a recombinant bacteriophage-derived
lysin with potent bactericidal activity against Staph aureus, a
major cause of blood stream infections, or bacteremia. CF-301 has
the potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus and does not impact the
body's natural bacterial flora. By targeting a conserved region of
the cell wall that is vital to bacteria, resistance is less likely
to develop to CF-301. Combinations of CF-301 with standard of care
antibiotics significantly increased bacterial killing and survival
in animal models of disease when compared to treatment with
antibiotics or CF-301 alone. In addition, in vitro and in vivo
experiments have shown that CF-301 is highly active against biofilm
infections. CF-301 was licensed from The Rockefeller University and
is being developed at ContraFect. It is the first lysin to enter
clinical studies in the U.S.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding CF-301
experimental data or results, our ability to discover and develop
protein and antibody therapeutics for life-threatening,
drug-resistant infectious diseases, our ability to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses, whether our
initial product candidates can treat antibiotic-resistant
infections such as MRSA and influenza, our ability to discover new
lysins targeting Gram-negative bacteria, the potential for CF-301
to be a treatment for Staph aureus bacteremia, including
endocarditis, and statements made regarding oral and poster
sessions. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel:
212-362-1200Email: matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024